Wistar Scientists Identify Esophageal Cancer Biomarkers
06 déc. 2023 10h09 HE
|
The Wistar Institute
Philadelphia, PA, Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wistar scientists have developed a new tool that can help identify cancer-associated microbes by using machine learning technology. Under the...
CARGO Therapeutics Announces Scientific Advisory Board
06 déc. 2023 08h05 HE
|
Cargo Therapeutics, Inc.
SAN MATEO, Calif., Dec. 06, 2023 (GLOBE NEWSWIRE) -- CARGO Therapeutics, Inc. (CRGX), a clinical-stage biotechnology company uniquely positioned to advance next generation, potentially curative cell...
U.S. Clinical Nutrition Market to Reach $7.56 Billion by 2030 | Coherent Market Insights (CMI)
05 déc. 2023 09h10 HE
|
CMI
Burlingame, Dec. 05, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, The U.S. clinical nutrition market was valued at US$ 4.93 Billion in 2023 and is forecast to reach a value of US$...
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board
05 déc. 2023 04h00 HE
|
AKAMPION
- Two renowned oncology experts to support the development of Thermosome's clinical candidate THE001 Munich, Germany – December 05, 2023 – Thermosome, a drug development company specializing...
Burning Rock Reports Third Quarter 2023 Financial Results
30 nov. 2023 01h25 HE
|
Burning Rock Biotech Limited
Burning Rock Reports Third Quarter 2023 Financial Results
Opioid Drugs Market to Surpass $56.5 billion by 2030: Coherent Market Insights (CMI)
29 nov. 2023 07h40 HE
|
CMI
Burlingame, Nov. 29, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, The global opioid drugs market was valued at US$ 45.0 Billion in 2023 and is forecast to reach a value of US$...
Valo Therapeutics Announces Regulatory Approval to Expand Phase I Immuno-oncology Trial into Sarcoma
29 nov. 2023 03h00 HE
|
Valo Therapeutics LTD
HELSINKI, Finland, Nov. 29, 2023 (GLOBE NEWSWIRE) -- Valo Therapeutics Oy (ValoTx), the developer of novel, adaptable immunotherapies for cancer, announces it has received approval from Germany’s...
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study
28 nov. 2023 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
27 nov. 2023 21h00 HE
|
AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 28, 2023 ...
AIM ImmunoTech Bolsters Intellectual Property Estate for Ampligen® with Issuance of Two Key U.S. Patents
27 nov. 2023 09h05 HE
|
AIM ImmunoTech Inc.
Extends certain exclusive U.S. rights to Ampligen for cancer and ME/CFS through 2039 Management discusses patent issuance and what this means in a brief video: here OCALA, Fla., Nov. 27, 2023 ...